Cantel acquires Accutron to boost dental offerings

Cantel Medical has acquired Accutron, which manufactures nitrous oxide delivery systems and single-use nasal masks. Cantel handed over approximately $52.5 million in cash in the deal.

“The addition of Accutron's portfolio of high quality, conscious sedation single-use nasal masks and equipment will further differentiate our infection prevention product offering,” said Jorgen Hansen, president and CEO of Cantel. “Single-use nasal masks are critical to eliminating cross-contamination of infectious pathogens between patients, and remains consistent with our strategy of providing customer solutions aimed at infection prevention and patient safety."

Cantel offers products and services aimed at infection prevention. The company “anticipates the acquisition to be accretive to GAAP and Non-GAAP earnings per share in the fiscal year ending July 31, 2017 and beyond,” Cantel said in the announcement. Accutron brought in $20.5 million in revenues for the calendar year ending in December 2015.


Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

The acquisition should help Cantel expand on its dental portfolio in Crosstex International, its healthcare disposables unit. The aim is for Accutron to help add a single-use disposable product line. This is Cantel’s first step into the dental equipment market.

Cantel’s acquisitions have given them a boost this year, according to an earnings call that took place back in June 2016. Accutron isn’t the first dental-focused acquisition for Cantel in 2016, as the company scooped up North American Science Associates’ (NAMSA) sterility assurance products division back in February.

“As we look forward we remain confident about the growth potential of the Healthcare Disposables business, driven by our increasing presence in the Sterility Assurance market now including the NAMSA acquisition, our entrance into the high growth Dental unit Waterline Disinfection market as well as for new opportunities in hospital and alternate care markets and in this market sales of Rapicide OPA/28 high level disinfectant in the United States more than doubled versus the prior year,” Andrew Krakauer, then CEO of Cantel, said during the June call. Krakauer handed the reins over to Hansen on June 31, 2016. At the time of the call, Hansen was president and chief operating officer at the company. 

The company plans to continue these strategic acquisitions moving forward, according to Hansen. “Overall we feel confident in our growth trends and see great opportunities for our businesses to grow organically. In addition, we will continue our prudent strategy of identifying, executing and integrating acquisitions worldwide,” Hansen said during the June call. “We're actually pursuing opportunities for acquisitions in all three of our major businesses as well as in new infection and prevention categories.”

- here's the press release
- here's the transcript from the June earnings call

Related Articles:
Cantel to buy endoscope cleanliness startup for $80M
Cantel Medical buys Italian healthcare manufacturer for $24.5M

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.